Articles tagged with Leukemia
Researchers from the University of Navarra have identified a link between specific gene mutations and more severe forms of leukemia. The study analyzed patients from 19 hospitals across Europe, confirming that these genetic alterations can be used to monitor disease progression and identify potential therapeutic targets.
T-ALL is caused by interplay of various factors including genetic errors that disrupt white blood cell formation. The study identifies PTPN2 as a tumor suppressor gene lost in leukemia patients, contributing to cancerous cell proliferation.
Researchers discover a combination of drugs that effectively target stubborn leukemia stem cells, which often escape standard treatment and lead to disease relapse. The study supports clinical trials of HDACi in combination with tyrosine kinase inhibitors to eliminate leukemia stem cells in patients with CML.
A consistent pattern in five genes has been found to predict the likelihood of relapse in pediatric T-cell acute lymphoblastic leukemia (T-ALL), allowing for more aggressive treatment to be administered from diagnosis. This discovery has significant potential to improve outcomes for patients at high risk of relapse.
Researchers identified a new drug target to inhibit genes vital for leukaemia cell growth, which could prevent disease progression. Targeting Stat5 may provide a novel therapeutic approach for treating acute and chronic leukaemias.
A gene regulator, miR-125b-2, has been identified as a key player in the development of leukemia typical of Down syndrome. The over-expression of this microRNA is found to be necessary for the disease's progression. Further studies suggest that miR-125b-2 silences tumor-suppression genes and regulatory microRNAs, spurting the leukemia.
Researchers at the University of Pennsylvania School of Medicine have found that mixed lineage leukemia (MLL) cancer cells rely on a normal version of an associated protein to stay alive. Deleting this gene from leukemia cells blocks uncontrolled growth triggered by a fusion protein, suggesting that it is essential for MLL proliferation.
A recent study reveals a significant increase in childhood leukemia cases in Basrah, southern Iraq, with rates doubling over 15 years compared to neighboring countries like Kuwait and the European Union. The authors hope their findings will pave the way for an investigation into potential causes of this alarming trend.
A team of researchers has identified a potential mechanism by which the tobacco-specific carcinogen NNK promotes lung tumor formation. They also found that statins may protect against invasive pneumococcal infections in children with sickle cell disease. Additionally, a new oncogenic protein called Nlp was discovered to be expressed at...
Researchers discovered a protein called MLL that bookmarks highly active genes in cells, enabling rapid gene reactivation after cell division. This finding may help understand how mutated MLL contributes to abnormal cell proliferation and differentiation in leukemia.
Researchers have identified a protein that can be disabled to prevent cancer cells from forming in children with mixed-lineage leukemia. The discovery could lead to the development of more effective treatments for this devastating disease.
Researchers identified partner genes that fuse with MLL, driving fatal leukemia in infants. Accurate predictions and treatments are expected based on this knowledge.
Researchers at the University of Illinois have discovered that soy peptide lunasin may help fight leukemia by activating a protein called caspase-3. Lunasin also showed anti-inflammatory properties by blocking the activation of NF-kappa-B and reducing interleukin-1 and interleukin-6 levels.
Researchers developed new tools to predict disease progression in acute childhood leukemia by analyzing DNA methylation patterns. The study found that specific genes' methylation levels correlate with treatment response, enabling identification of patients at risk of relapse.
Researchers have discovered a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that is particularly common in children with Down syndrome. The finding has led to the development of new diagnostic tests and potential treatments, including an experimental medication targeting one of the altered genes.
A new technology using Superconducting Quantum Interference Device (SQUID) enhances the ability to detect leukemia cells in bone marrow, increasing sensitivity by at least 10-fold. This improves minimal residual disease measurements and will determine more precisely the effect of chemotherapy.
Recent findings published online first in Cancer Research show that obesity is associated with increased incidence and mortality of leukemia in children. The study reveals that fat cells can block chemotherapy drugs from reaching cancerous cells, leading to reduced treatment effectiveness.
A Syracuse University research team discovered a second molecular switch within the Mixed Lineage Leukemia protein complex, which could be exploited to prevent abnormal cell production. The W-RAD switching mechanism signals cells to create multiple copies of cancer cells.
A new analysis reveals that adolescents and young adults with blood-related cancers have better long-term survival rates than those diagnosed in the 1980s. However, survival rates in this age group are still lower than those seen in younger children and some older adults.
A new study suggests that changes in gene expression called epigenetic alterations can serve as markers for detecting CLL early and monitoring its progression. Researchers also point to a strategy for treating the disease earlier using drugs that reverse such changes.
A groundbreaking clinical trial has shown that exercise can significantly improve symptoms of fatigue and depression, increase cardiovascular endurance, and maintain quality of life for adult leukemia patients undergoing treatment. The study demonstrated a substantial reduction in total fatigue and depression scores, as well as improve...
Researchers at Tel Aviv University have discovered a novel treatment for children with high-risk leukemia, leveraging a similar mutation linked to Down syndrome and polycythemia vera in adults. The JAK2 inhibitor offers promise as an alternative to chemotherapy, potentially reducing toxicity costs.
Researchers at MGH identified a chromosomal abnormality that leads to acute lymphoblastic leukemia (ALL) in children. The mutation affects hematopoietic stem cells and can lead to years-later cancer development.
Janet Davison Rowley's work established cancer as a genetic disease through discoveries of recurrent chromosomal abnormalities in leukemias and lymphomas. Her findings revolutionized how cancer is understood and treated, leading to more precise diagnoses and effective treatments.
A new study has identified a key protein receptor responsible for tumor cells invading the brain and spinal cord in childhood leukemia. The finding may lead to new drugs that block this receptor and reduce the risk of relapse in some leukemia patients.
Researchers at Mayo Clinic have found that patients with chronic lymphocytic leukemia (CLL) can tolerate high doses of green tea extract EGCG, leading to a significant reduction in lymphocyte count. The study also showed that many participants experienced regression of CLL symptoms, particularly those with enlarged lymph nodes.
The Cole Foundation has pledged $2.5 million to support up-and-coming researchers in pediatric leukemia research at the University of Montreal, McGill University, and the Institut Armand-Frappier. This investment will create new grants, awards, a cell bank, and fellowships to accelerate the fight against pediatric leukemia.
Researchers have pinpointed a new class of gene mutations that identify cases of childhood acute lymphoblastic leukemia with a high risk of relapse and death. The discovery suggests specific drugs could treat this subtype, building on previous studies hinting at kinases' role in the disease.
The Shilatifard Lab has provided new insight into H3K4 methylation, a crucial activity associated with MLL protein and chromosomal translocations. The study sheds light on how this process contributes to the development of aggressive infant acute leukemias.
A retrospective study of 2,854 Italian patients with MS found leukemia occurred in .74% of those treated with mitoxantrone, significantly higher than previously reported rates. The study highlights the need for careful hematological follow-up to check for acute leukemia.
Scientists discovered a potential new biomarker, PDE7B, to predict the aggressiveness of chronic lymphocytic leukemia (CLL). High levels of PDE7B in white blood cells indicate aggressive CLL and need immediate treatment.
Researchers have discovered that biphosphonates can prevent radiation-induced leukemia in laboratory mice, with 75% of treated mice developing the disease compared to 100% in untreated mice. The study suggests that these compounds may have a general effect on leukemia associated with causes other than radiation.
Researchers discovered the JunB gene's role in regulating hematopoietic stem cells, which produce blood cells. The study suggests that JunB can help prevent leukemia by limiting cell proliferation and differentiation.
Researchers identify LIPG gene mutations that result in elevated HDL-C levels, potentially increasing cardiovascular risk. Meanwhile, a new study suggests intermittent IL-7 therapy may boost CD4+ T cell counts in HIV-infected patients.
A study led by St. Jude Children's Research Hospital identified mutations in the IKZF1 gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). The findings suggest that this genetic marker could be used to tailor treatment intensity and improve patient outcomes.
A study by researchers from the University of Kentucky found that grape-seed extract induces apoptosis in leukemia cells by activating the JNK pathway, leading to cell cycle regulation and death. The extract has shown promise as a potential agent for preventing or treating hematological malignancies.
Leukemia takes over bone marrow niches, crowding out healthy stem cells. Blocking cancer cell chemical signals could help protect stem cells and improve treatment strategies. Researchers develop approach to blunt leukemia's effect on stem cells, potentially boosting immune system response.
Researchers discovered the MLL-AF4 protein binds to over 169 genes in cancer cells, hijacking blood stem cell machinery and causing cancerous cell division. This understanding may lead to new drug targets for treating mixed-lineage leukemia.
Researchers at M.D. Anderson Cancer Center report encouraging results from clinical trials of second-generation CML drugs nilotinib and dasatinib. These drugs have shown higher complete cytogenetic response rates compared to the frontline medication imatinib, with some patients achieving responses faster than ever seen before.
Two REVLIMID Phase II studies showed significant activity and tolerability in previously untreated CLL patients, achieving response rates of 52% and 96% with manageable side effects. The studies also indicated that continued treatment can improve response rates.
In a phase II clinical trial, lenalidomide demonstrated activity against chronic lymphocytic leukemia in elderly patients. The drug showed a favorable toxicity profile and achieved significant responses, including partial response in 54% of patients.
Novel treatments, including fostamatinib disodium, have shown significant clinical activity in treating leukemia and lymphoma. The study found improved response rates and prolonged stable disease in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Four studies showcase treatment advances in blood cancers, including improved progression-free survival for patients with relapsed or refractory chronic lymphocytic leukemia. A new tumor suppressor gene is also discovered in patients with myeloproliferative disorders.
Men who survived childhood leukemia treatment into adulthood have lower bone mineral density, increasing their risk of osteoporosis. The study found that male survivors were more likely than female survivors to have weaker bones, and shorter individuals also faced higher risks.
Researchers at UCSD have discovered a novel drug target, phosphodiesterase 7B (PDE7B), for treating chronic lymphocytic leukemia (CLL). Blocking PDE7B increases cAMP levels and causes CLL cells to undergo programmed cell death.
Researchers identified two genes that sensitize lymphoid progenitor cells to the effects of aging and confer resistance to leukemogenesis. These genes regulate cell cycle progression and mediate senescence and tumor suppression in aged cells.
A recent study published in Cancer Cell reveals a potential therapeutic approach for MLL-AF4 leukemias, a subtype of acute lymphoblastic leukemia that accounts for 70% of infant cases. By inhibiting the histone-modifying enzyme DOT1L, researchers hope to reverse cancer-promoting genes and improve treatment outcomes.
Researchers at Stanford University School of Medicine have developed a new diagnostic test that can identify rare leukemias in hours instead of weeks. The test uses cell-signaling pathways to decipher potentially dangerous molecular conversations, offering a more reliable assessment of risk and potential treatment options.
Researchers at Stanford University School of Medicine have discovered a novel 'double agent' role for glycogen synthase kinase 3 (GSK3) in regulating cell growth. Inhibiting GSK3 combats leukemias caused by mutated MLL genes, which account for five to 10 percent of child and adult leukemias.
Advances in treatment have led to increased long-term survival for US children diagnosed with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma. Period analysis reveals improved survival rates between 1990 and 2004, with projections suggesting continued progress through molecularly targeted therapies.
Researchers explore new treatments for psoriasis, revealing a potential therapeutic option in AEB071, while cautioning further clinical trials are needed. Additionally, studies uncover the reasons behind gene therapy complications in SCID patients, shedding light on insertional oncogenesis and acquired somatic mutations.
Researchers discover that Angiocidin can differentiate leukemia cells into a normal, macrophage-like phenotype, making them susceptible to chemotherapy treatment. The protein also stimulates the immune system by up-regulating genes characteristic of immune cells.
Research by VIB-K.U.Leuven scientists finds that location in cell affects carcinogenicity of NUP214-ABL1 protein, a kinase linked to T-cell acute lymphoblastic leukemia. This discovery opens new avenues for targeted therapies and potential treatment approaches.
Researchers found that LYN kinase activation is associated with imatinib resistance in CML patients, a mechanism not explained by BCR-ABL mutations. Blocking LYN kinase restores imatinib responsiveness and triggers cell death.
A new mathematical model could lead to personalized vaccines for CML patients, strengthening the immune system during its weakest point. The study uses data from four years of imatinib therapy and recommends 'cancer vaccines' to combat drug resistance.
Researchers have developed a mathematical model that predicts optimal timing for a cancer vaccine in CML patients based on their immune response, which may lead to a cure. The model suggests boosting the immune system at a specific time when it starts weakening can provide a strong stimulation to combat leukemia cells.
A Phase 2 clinical trial of GCS-100, a polysaccharide targeting galectin-3, demonstrates apoptosis induction and reduced leukocyte counts in relapsed CLL patients. The treatment was generally well tolerated with mild-to-moderate adverse events.
Researchers have identified a combination of novel anti-cancer compounds that can kill chronic myelogenous leukemia cells previously resistant to conventional therapy. The combination involves a Bcr/Abl kinase inhibitor and a histone deacetylase inhibitor, which work together to induce programmed cell death in CML cells.
Researchers at UCLA identified a type of leukemia stem cell and uncovered the genetic mechanisms that cause normal blood stem cells to become cancerous. This discovery may lead to new therapies targeting these stem cells, potentially curing certain cancers.
The study found that a combination of genetic mutations, including the deletion of gene IKZF1, can initiate most cases of an aggressive form of acute lymphoblastic leukemia. The researchers also identified cooperation between these genetic lesions and BCR-ABL1 expression.